GET DAILY SIGNALSClorox (CLX) Delivers Solid First-Quarter Results on GOJO Acquisition Strength
Key Takeaways
- Net sales rose 33% year over year to $1.91 billion, topping analyst consensus, with the GOJO (Purell) acquisition contributing roughly 15 points of growth.
- Adjusted EPS surged 82% to $1.55, well above the roughly $1.07 Wall Street estimate.
- GAAP diluted EPS was $1.39, up from $0.65 in the year-ago quarter.
- Gross margin contracted 130 basis points to 40.4%, pressured by higher commodity, manufacturing and logistics costs.
- Management kept its full-year adjusted EPS outlook of $5.70 to $6.00 but now expects results to land closer to the low end of the range.
Earnings Context and Why It Matters
Clorox's first-quarter fiscal 2027 results, covering the period ended September 30, 2026, mark a pivotal checkpoint in the company's post-digital-transformation and acquisition strategy. The quarter reflects the first full integration of GOJO, the maker of Purell, which closed in April 2026 and has shifted CLX's portfolio further toward health and wellness. It also laps a year-ago period depressed by an inventory drawdown tied to the company's U.S. ERP system transition. Investors are watching whether the top-line lift from GOJO and a recovering base business can outpace mounting input-cost inflation, and whether CLX can rebuild margins while holding onto hard-won market share. I checked sector comparisons using Tickeron's AI Screener to see how the stock stacks up against peers.
Reported Results
CLX reported net sales of $1.91 billion, up 33% from the prior-year quarter and ahead of the roughly $1.88 billion consensus. Organic sales increased 18%, reflecting the benefit of lapping the ERP transition-related inventory drawdown in the year-ago quarter. GOJO contributed approximately 15 points to total sales growth.
GAAP diluted EPS was $1.39, a 114% increase from $0.65 a year earlier. Adjusted EPS, a non-GAAP measure that excludes acquisition and integration costs, rose 82% to $1.55, comfortably exceeding the roughly $1.07 analyst estimate. The beat was driven by higher net sales, cost savings and a lower tax rate, partially offset by higher commodity, manufacturing and logistics costs.
Gross margin, however, declined 130 basis points to 40.4% from 41.7%, reflecting inflationary headwinds and GOJO integration expenses. By segment, Health and Wellness sales rose 62% (with GOJO adding about 39 points), Household rose 17%, Lifestyle rose 16%, and International rose 11%, including 9% organic growth.
For the full year, the company maintained its adjusted EPS outlook of $5.70 to $6.00 and its net sales growth guidance of 13% to 14%, but lowered its gross margin expectation to about 41.5% and now anticipates adjusted EPS results closer to the low end of the range. I also reviewed related signals with Tickeron's AI Daily Buy/Sell Signals for additional context on the name.
Market Reaction and Investor Sentiment
Heading into the report, sentiment was cautiously optimistic, with analysts bracing for a steep year-over-year recovery driven by the GOJO deal and the ERP comparison lap. The outsized adjusted EPS beat, roughly 48 cents above consensus, underscored the strength of the top-line rebound, while the 33% sales jump validated the strategic rationale behind the Purell acquisition. At the same time, the market is likely to weigh the guidance nuance carefully: management kept its full-year adjusted EPS range intact but signaled results are now expected closer to the low end, citing a more challenging cost environment. That combination of strong current-quarter momentum and softer margin expectations is a key driver of how investors interpret the stock's next move.
Forward Outlook and Key Factors to Monitor
Looking ahead, the central theme is whether CLX can rebuild profitability while sustaining the consumption and market-share momentum it has begun to show. Management expects full-year organic sales growth of about 3.5% to 4.5%, though that includes more than 3.5 points of benefit from lapping the prior-year ERP-related drawdown, implying underlying growth that is roughly flat to slightly positive.
On costs, the company is leaning on productivity and cost savings, which reached one of the highest quarterly levels on record, while planning targeted pricing and revenue-growth-management actions that are expected to phase in more heavily during the back half of the fiscal year. Gross margin is now projected at about 41.5% for the year, reflecting higher-than-normal inflation and negative mix.
Investors should monitor commodity and logistics cost trends, the pace of GOJO integration and synergies under the combined Clorox Purell ProCare business, interest expense tied to the debt-financed acquisition, and whether pricing actions can offset input-cost pressure without sacrificing share gains. Category demand and consumer value-seeking behavior will also remain important signposts as the year progresses.
Using AI Tools in My Research Process
In my own work, I frequently turn to Tickeron's AI Screener to filter opportunities across consumer staples and spot setups that align with earnings momentum or margin trends. It allows quick scans for technical patterns, fundamentals, and AI signals, helping me cross-check ideas like the ones emerging from CLX's latest print without spending hours on manual review. This kind of tool has become a regular part of how I evaluate names in the space.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CLX in downward trend: price expected to drop as it breaks its higher Bollinger Band on October 29, 2026
CLX broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 32 similar instances where the stock broke above the upper band. In 24 of the 32 cases the stock fell afterwards. This puts the odds of success at 75%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CLX's RSI Indicator exited the oversold zone, 17 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 49%.
The Momentum Indicator moved above the 0 level on October 08, 2026. You may want to consider a long position or call options on CLX as a result. In 48 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 49%.
The Moving Average Convergence Divergence (MACD) for CLX just turned positive on October 05, 2026. Looking at past instances where CLX's MACD turned positive, the stock continued to rise in 22 of 47 cases over the following month. The odds of a continued upward trend are 47%.
CLX moved above its 50-day moving average on October 29, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLX advanced for three days, in 180 of 319 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
The Aroon Indicator entered an Uptrend today. In 75 of 193 cases where CLX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 39%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 10 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 38 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. CLX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CLX's P/B Ratio (118.244) is slightly higher than the industry average of (20.608). P/E Ratio (18.257) is within average values for comparable stocks, (17.011). Projected Growth (PEG Ratio) (1.019) is also within normal values, averaging (1.518). Dividend Yield (0.057) settles around the average of (0.033) among similar stocks. P/S Ratio (1.542) is also within normal values, averaging (1.902).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of detergent and cleaning products
Industry HouseholdPersonalCare
Advertisement